or aerosol challenge with virulent type A and type B strains of the pathogen. Vaccine 20: 3465–3470. 14. Conlan JW, Vinogradov E, Monteiro MA, Perry MB (2003) Mice intradermally- inoculated with the intact lipopolysaccharide, but not the lipid A or O-chain, from Francisella tularensis LVS rapidly acquire varying degrees of enhanced resistance against systemic or aerogenic challenge with virulent strains of the pathogen. Microb Pathog 34: 39–45. 15. Dreisbach VC, Cowley SC, Elkins KL (2000) Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon. Infect Immun 68: 1988–1996. 16. Fulop M, Mastroeni P, Green M, Titball RW (2001) Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine 19: 4465–4472. 17. Cole LE, Yang Y, Elkins KL, Fernandez ET, Qureshi N, et al. (2009) Antigen- specific B-1a antibodies induced by Francisella tularensis LPS provides long-term protection against F. tularensis LVS challenge. PNAS 106: 4343–4348. 18. Fulop M, Manchee R, Titball RW (1995) Role of lipopolysaccharide and a major outer membrane protein from Francisella tularensis in the induction of immunity against tularemia. Vaccine 13: 1220–1225. 19. Golovliov I, Ericsson M, Akerblom L, Sandstrom G, Tarnvik A, et al. (1995) Adjuvanticity of ISCOMs incorporating a T cell-reactive lipoprotein of the facultative intracellular pathogen Francisella tularensis. Vaccine 13: 261–267. 20. Hartley MG, Green M, Choules G, Rogers D, Rees DG, et al. (2004) Protection afforded by by heat shock protein 60 from Francisella tularensis is due to copurified lipopolysaccharide. Infect Immun 72: 4109–4113. 21. Huntley JF, Conley PG, Rasko DA, Hagman KE, Apicella MA, et al. (2008) Native outer membrane proteins protect mice against pulmonary challenge with virulent type A Francisella tularensis. Infect Immun 76: 3664–3671. 22. Gregory SH, Chen WH, Mott S, Palardy JE, Parejo NA, et al. (2010) Detoxified Endotoxin Vaccine (J5dLPS/OMP) Protects Mice Against Lethal Respiratory Challenge with Francisella tularensis SchuS4. Vaccine doi:10.1016/j.vaccine. 2010.01.067. 23. Bitsaktsis C, Rawool DB, Li Y, Kurkure NV, Iglesias B, et al. (2009) Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensis. J Immunol 182: 4899–4909. 24. Tschernig T, Pabst R (2000) Bronchus-asscoated lymphoid tissue (BALT) is not present in the normal adult lung but in different diseases. Pathobiology 68: 1–8. 25. Bienenstock J, Johnston N, Perey DY (1973) Bronchial lymphoid tissue. I. Morphologic characteristics. Lab Invest 28: 686–692. 26. Bienenstock J, Johnston N, Perey DY (1973) Bronchial lymphoid tissue. II. Functional characteristics. Lab Invest 28: 693–698. 27. Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, Hartson L, Sprague F, et al. (2004) Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med 10: 927–234. 28. Bienenstock J, McDermott MR (2005) Bronchus- and nasal-associated lymphoid tissues. Immunol Rev 206: 22–31. 29. Rangel-Moreno J, Moyron-Quiroz JE, Carragher D, Randall TD (2007) Role of lymphotoxin and homeostatic chemokines in the development and function of locale lymhpid tissue in the respiratory tract. Immunologia 26: 13–28. 30. Kahnert A, Hopken UE, Stein M, Bandermann S, Lipp M, et al. (2007) Mycobacterium tuberculosis triggers formation of lymphoid structure in murine lungs. J Infect Dis 195: 46–54. 31. Rodriguez F, Fernandez A, Oros J, Ramirez AS, Luque R, et al. (2001) Changes in lymphocyte subsets in the bronchus-associated lymphoid tissue of goats naturally infected with different Mycoplasma species. J Vet Med B Infect Dis Vet Public Health 48: 259–266. Tularemia Vaccination and BALT 32. Iwata M, Sato A (1991) Morphological and Immunohistochemical Studies in the Lungs of and Bronchus-Associated Lymphoid Tissue in a Rat Model of Chronic Pulmonary Infection with Pseudomonas aeruginosa. Infect Imm 59: 1514–1520. 33. Chen HD, Fraire AE, Joris I, Welsh RM, Selin LK (2003) Specific history of heterologus virus infections determines anti-viral immunity and immunopathol- ogy in the lung. Am J Pathol 163: 1341–1355. 34. Rangel-Moreno J, Hartson L, Navarro C, Gaxiola M, Selman M, et al. (2006) Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. J Clin Invest 116: 3183–3194. 35. Csaba N, Garcia-Fuentes M, Alonso MJ (2009) Nanoparticles for nasal vaccination. Adv Drug Deliv Rev 61: 140–157. 36. GeurtvanKessel CH, Willart MA, Bergen IM, van Rijt LS, Muskens F, et al. (2009) Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J Exp Med 206: 2339–2349. 37. Suda T, Chida K, Hayakawa H, Imokawa S, Iwata M, et al. (1999) Development of Bronchus-Associated Lymphoid Tissue in Chronic Hypersen- sitivity Pneumonitis. Chest 115: 357–363. 38. Sato A, Chida K, Iwata M, Hayakawa H (1992) Study of bronchus associated lymphoid tissue in chronic in patients with diffuse panbronchiolitis. Am Rev Respir Dis 146: 473–478. 39. Conlan JW, Shen H, KuoLee R, Zhao X, Chen W (2005) Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism. Vaccine 23: 2477–2485. 40. Chiavolini D, Alroy J, King CA, Jorth P, Weir S, et al. (2008) Identification of immunologic and pathologic parameters of death versus survival in respiratory tularemia. Infect Immun 76: 486–496. 41. Mohr E, Serre K, Manz RA, Cunningham AF, Khan M, et al. (2009) Dendritic cells and monocyte/macrophages that create the IL-6/APRIL-Rich lymph node microenvironments where plasmablasts mature. J Immunol 182: 2113–2123. 42. Randall TD (2010) Pulmonary dendritic cells: thinking globally, acting locally. J Exp Med 207: 451–454. 43. Rangel-Moreno J, Moyron-Quiroz JE, Hartson L, Kusser K, Randall TD (2007) Pulmonary expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC ligand 21 is essential for local immunity to influenza. PNAS 104: 10577–10582. 44. Tschernig T, Pabst R (2009) What is the clinical relevance of different lung compartments? BMC Pulm Med 9: 39. 45. Ulrichs T, Kosmiadi GA, Trusov V, Jorg S, Pradl L, et al. (2004) Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J Pathol 204: 217–228. 46. Pabst R (2007) Plasticity and heterogeneity of lymphoid organs. What are the criteria to call a lymphoid organ primary, secondary or tertiary? Immunol Lett 112: 1–8. 47. Moyron-Quiroz JE, Rangel-Moreno J, Hartson L, Kusser K, Tighe MP, et al. (2006) Persistence and responsiveness of immunologic memory in the absence of secondary lymphoid organs. Immunity 25: 643–654. 48. Turner DL, Cauley LS, Khanna KM, Lefrancois L (2007) Persistent antigen presentation after acute vesicular stomatitis virus infection. J Virol 81: 2039–2046. 49. Jelley-Gibbs DM, Brown DM, Dibble JP, Haynes L, Eaton SM, et al. (2005) Unexpected prolonged presentation of influenza antigens promotes CD4 T cell memory generation. J Exp Med 202: 697–706. 50. Qi HL, Tai JY, Blake MS (1994) Expression of large amounts of neisserial porin proteins in Escherichia coli and refolding of the proteins into native trimers. Infect Immun 62: 2432–2439. 51. Massari P, King CA, MacLeod H, Wetzler LM (2005) Improved purification of native meningococcal porin PorB and studies on its structure/function. Protein Expr Purif 44: 136–146. PLoS ONE | www.plosone.org 13 June 2010 | Volume 5 | Issue 6 | e11156